PTH treatment in hypoparathyroidism.

Abstract

Hypoparathyroidism (HypoPT) is one of the few major hormone deficiency diseases that are not usually treated with the missing hormone. Bovine parathyroid hormone (PTH) has been purified and used as experimental treatment, as long back as in 1928 by Fuller Albright. Treatment, however, was abolished mainly because of antibody formation and costs. The recent approval of fully humanized truncated parathyroid hormone (Teriparatide, PTH (1-34)) and intact parathyroid hormone (Preotact, PTH(1-84)) for treatment of osteoporosis, has made the PTH drugs more accessible and thereby made clinical trials with PTH treatment of HypoPT feasible. Resent clinical trials have shown that treatment with PTH (1-34) and PTH (1-84) can stabilize plasma calcium, normalize plasma phosphate and reduce urine excretion of calcium. Furthermore, it seems that some patients with hypoPT experience an improved quality of life when treated with PTH compared with conventional treatment with 1α-hydroxylated vitamin D metabolites and calcium supplements.

• Authors: Tanja Sikjaer, Lars Rejnmark, Leif Mosekilde
• Journal: Current drug safety (Curr Drug Saf) Vol. 6 Issue 2 Pg. 89-99 (Apr 2011) ISSN: 2212-3911 [Electronic] United Arab Emirates
• PMID: 21524246 (Publication Type: Comparative Study, Journal Article, Review)

Chemical References

• Parathyroid Hormone
• Phosphates
• Teriparatide
• Vitamin D
• Calcium

Topics

• Animals
• Calcium (administration & dosage, blood)
• Cattle
• Humans
• Hypoparathyroidism (drug therapy, physiopathology)
• Parathyroid Hormone (therapeutic use)
• Phosphates (blood)
• Quality of Life
• Teriparatide (therapeutic use)
• Vitamin D (analogs & derivatives, therapeutic use)